On "diagnostic value of aberrant gene methylation in stool samples for colorectal cancer or adenomas"

This is the author's manuscript

Original Citation:

Availability:
This version is available http://hdl.handle.net/2318/1557753 since 2018-10-30T17:51:49Z

Terms of use:
Open Access
Anyone can freely access the full text of works made available as "Open Access". Works made available under a Creative Commons license can be used according to the terms and conditions of said license. Use of all other works requires consent of the right holder (author or publisher) if not exempted from copyright protection by the applicable law.

(Article begins on next page)
This is an author version of the contribution published on:
Questa è la versione dell’autore dell’opera:
[Panminerva Medica, 58 (1), 2016]
ovvero [Caviglia Gian Paolo, Pellicano Rinaldo, 58, Minerva Medica, 2016, pag.102]

The definitive version is available at:
La versione definitiva è disponibile alla URL:
[https://www.minervamedica.it/en/journals/panminerva-medica/index.php]
On the diagnostic value of aberrant gene methylation in stool samples for colorectal cancer or adenomas: a meta-analysis

G. P. CAVIGLIA¹, R. PELLICANO²

¹Department of Medical Sciences, University of Turin, Turin, Italy
²Department of Gastroenterology and Hepatology, Città della Salute e della Scienza, Molinette Hospital, Turin, Italy

Corresponding author: Gian Paolo Caviglia, Department of Medical Sciences, University of Turin, Via Cavour 31, Turin 10100, Italy. Tel: +39 (0)11 6333922; Fax: +39 (0)11 6333976; e-mail: caviglia.giampi@libero.it

Conflict of interest statement: None to declare

Key words: Colorectal cancer; Adenoma; DNA methylation.
Dear Editor,

Colorectal cancer (CRC) is the third most frequent cancer in humans and more than 90% of cases originate from colorectal adenoma.\(^1\) The malignant evolution into CRC is characterized by a sequential process of genetic and epigenetic alterations in colocytes. Recently, the growing interest towards epigenetic regulation of gene expression, led to the identification of different potential epigenetic biomarkers of CRC. In particular, DNA methylation represent one of the most investigated biological event involved CRC development bearing potential clinical implications for CRC diagnosis, prognosis and response to treatment.\(^2\)

In a recent interesting paper, Yuan and colleagues evaluated the diagnostic accuracy of stool DNA methylation detection for CRC and adenoma performing a meta-analysis.\(^3\) According to selection criteria adopted, authors included 13 studies for a total of 716 patients with CRC, 220 with adenoma and 414 healthy subjects. Seven studies assessed the methylation status of a single gene whereas 6 studies evaluated a panel of various genes. Moreover, different methylation detection techniques were used including methylation-specific PCR, methylation-sensitive high-resolution melting and microarray DNA methylation assay followed by pyrosequencing. Finally, area under the summary receiver operator characteristic curve values of 0.9385 and 0.9438 for adenoma and CRC detection were estimated, respectively, indicating a high diagnostic accuracy for fecal gene methylation testing.\(^3\)

Although the authors performed a meta-regression analysis that showed no effect of heterogeneity on diagnostic accuracy, in our opinion both underlying differences in biomarkers tested and in assay methods inevitably led to unreliable results. In fact, included studies were carried out by using 3 different techniques as many several target genes (alone or combined into panels) not allowing a proper results comparison.

Considering that hundreds of genes are aberrantly methylated in the setting of CRC and standardized testing protocols are still required, we suggest that further meta-analysis should be performed with a more precise study selection criteria.
References

